72.11.Z - Scientific research and development activities
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
70.22.Z - Head office activities and management consultancy
71.12.Z - Engineering activities and related technical consultancy
71.20.A - Food quality testing and analysis
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.19.Z - Scientific research and development activities
74.90.Z - Other professional, scientific and technical activities, not elsewhere classified
2020 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 0,4 | 2,1 | -0,5 | -122,9 |
EBITDA | 0,4 | 2,2 | -0,4 | -119 |
Short time liabilities | 0,2 | 0,3 | 0,6 | 82,6 |
Equity capital | 2,5 | 2 | 3,6 | 78 |
Operating profit (EBIT) | 0,4 | 2,2 | -0,4 | -119,2 |
Assets | 8,5 | 8,4 | 8,1 | -3,6 |
Net profit (loss) | 0,3 | 2,1 | -0,5 | -122,9 |
Cash | 0,1 | 0,7 | 0,3 | -54,6 |
Net income from sale | 0,7 | 0,1 | 0 | -89,2 |
Liabilities and provisions for liabilities | 6 | 6,4 | 4,5 | -29,3 |
Working assets | 0,2 | 0,8 | 0,4 | -48,9 |
Depreciation | 0 | 0 | 0 | 23,7 |
% | % | % | p.p. | |
Profitability of capital | 13,5 | 104,9 | -13,5 | -118,4 |
Equity capital to total assets | 29,7 | 24 | 44,2 | 20,2 |
Gross profit margin | 58,3 | 1741,6 | -3697 | -5438,6 |
EBITDA Margin | 67,4 | 1799,7 | -3178,5 | -4978,2 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 117 | 1033 | 17 533 | 16 500 |
Current financial liquidity indicator | 0.030513936653733253 | 0.1534223109483719 | 0.12304501980543137 | -0,1 |
Net dept to EBITDA | 2.078563690185547 | 0.22252511978149414 | -2.7439217567443848 | -2,9 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane